TS-042666 — The discovery of a novel treatment for EGFR TKI drug resistance in NSCLC.
Non-small cell lung cancer (NSCLC), which accounts for 85% of all lung cancers, is one of the leading causes of cancer-related death. Substantial progress has been made in the management of NSCLC as several driver mutations have been identified in cell communication pathways involved in lung tumor…
